1. B. Boisselier, Y. Marie, S. El Hallani, G. Kaloshi, A. Iershov, V. Kavsan, D. Psimaras, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. J Neurooncol, 94(2):169-72, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW]



2. G. Kaloshi, R. Guillevin, N. Martin-Duverneuil, F. Laigle-Donadey, D. Psimaras, Y. Marie, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri. Neurology, 73(6):445-9, 2009. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology/therapeutic use, Cell Movement/physiology, Cerebral Cortex/drug effects/*pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Neuroepithelial/*diagnosis/*drug therapy/mortality/pathology, Neuroglia/pathology, Predictive Value of Tests, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult.



3. G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, A. Idbaih, F. Ducray, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology, 70(8):590-5, 2008. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating/*therapeutic use, Chromosome Mapping, *Chromosomes, Human, Pair 19, Cohort Studies, DNA Mutational Analysis, Dacarbazine/*analogs & derivatives/therapeutic use, Disease-Free Survival, Female, Genetic Markers/physiology, Humans, Male, Middle Aged, Neoplasms, Neuroepithelial/*drug therapy/*genetics, O(6)-Methylguanine-DNA Methyltransferase/*metabolism, Prognosis, Retrospective Studies, Tumor Markers, Biological.



4. C. Carpentier, J. Lejeune, F. Gros, S. Everhard, Y. Marie, G. Kaloshi, F. Laigle-Donadey, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol, 84:249-253, 2007. Note: Journal article. [WWW]



5. E. Criniere, G. Kaloshi, F. Laigle-Donadey, J. Lejeune, N. Auger, A. Benouaich-Amiel, S. Everhard, K. Mokhtari, M. Polivka, J. Y. Delattre, K. Hoang-Xuan, J. Thillet, and M. Sanson. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol, 83:173-179, 2007. Note: Journal article. [WWW]



6. G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M. A. Renard, W. Iraqi, A. Idbaih, S. Paris, L. Capelle, H. Duffau, P. Cornu, J. M. Simon, K. Mokhtari, M. Polivka, A. Omuro, A. Carpentier, M. Sanson, J. Y. Delattre, and K. Hoang-Xuan. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology, 68(21):1831-6, 2007. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/administration & dosage, Brain Neoplasms/*drug therapy/*genetics/physiopathology, *Chromosome Deletion, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, DNA Mutational Analysis, Dacarbazine/administration & dosage/*analogs & derivatives, Drug Resistance, Neoplasm/*genetics, Female, Gene Expression Regulation, Neoplastic/drug effects/genetics, Genetic Screening, Genotype, Glioma/*drug therapy/*genetics/physiopathology, Humans, Loss of Heterozygosity/genetics, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy/genetics, Retrospective Studies, Survival Rate, Treatment Outcome.



7. G. Kaloshi, K. Mokhtari, C. Carpentier, S. Taillibert, J. Lejeune, Y. Marie, J. Y. Delattre, R. Godbout, and M. Sanson. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol, 84:215-8, 2007. Note: Journal article. [WWW]



8. D. Ricard, G. Kaloshi, A. Amiel-Benouaich, J. Lejeune, Y. Marie, E. Mandonnet, M. Kujas, K. Mokhtari, S. Taillibert, F. Laigle-Donadey, A. F. Carpentier, A. Omuro, L. Capelle, H. Duffau, P. Cornu, R. Guillevin, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol, 61(5):484-90, 2007. Note: Journal ArticleUnited States. [WWW]



9. E. Vauleon, N. Auger, A. Benouaich-Amiel, F. Laigle-Donadey, G. Kaloshi, J. Lejeune, J. Y. Delattre, J. Thillet, and M. Sanson. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172(1):33-7, 2007. Note: Journal ArticleUnited States. [WWW]



10. C. Carpentier, F. Laigle-Donadey, Y. Marie, N. Auger, A. Benouaich-Amiel, J. Lejeune, G. Kaloshi, J. Y. Delattre, J. Thillet, and M. Sanson. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology, 67(5):872-4, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Alleles, Chi-Square Distribution, Female, Follow-Up Studies, Gene Frequency, Glioblastoma/*genetics, Humans, Male, Middle Aged, Odds Ratio, *Polymorphism, Genetic, Promoter Regions (Genetics)/*genetics, Prospective Studies, RNA, Messenger/metabolism, Receptor, Epidermal Growth Factor/*genetics, Reverse Transcriptase Polymerase Chain Reaction/methods, Risk Factors, Sp1 Transcription Factor/*metabolism, Survival Analysis.



11. S. Everhard, G. Kaloshi, E. Criniere, A. Benouaich-Amiel, J. Lejeune, Y. Marie, M. Sanson, M. Kujas, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, and J. Thillet. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol, 60(6):740-3, 2006. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/pharmacology/therapeutic use, Brain Neoplasms/diagnosis/*drug therapy/genetics, DNA Methylation/*drug effects, DNA Mutational Analysis, Dacarbazine/*analogs & derivatives/pharmacology/therapeutic use, Disease Progression, Female, Genetic Markers/drug effects/genetics, Glioma/diagnosis/*drug therapy/genetics, Humans, Male, Middle Aged, Neoadjuvant Therapy, Predictive Value of Tests, Prognosis, Promoter Regions (Genetics)/*drug effects/genetics, Survival Rate, Tumor Markers, Biological/*genetics, Tumor Suppressor Protein p14ARF/*genetics.

This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All person copying this information are expected to adhere to the terms and constraints invoked by each author's copyright. In most cases, these works may not be reposted without the explicit permission of the copyright holder.

Les documents contenus dans ces répertoires sont rendus disponibles par les auteurs qui y ont contribué en vue d'assurer la diffusion à temps de travaux savants et techniques sur une base non-commerciale. Les droits de copie et autres droits sont gardés par les auteurs et par les détenteurs du copyright, en dépit du fait qu'ils présentent ici leurs travaux sous forme électronique. Les personnes copiant ces informations doivent adhérer aux termes et contraintes couverts par le copyright de chaque auteur. Ces travaux ne peuvent pas être rendus disponibles ailleurs sans la permission explicite du détenteur du copyright.

This document was translated from BibT_EX by bibtex2html